Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
9
×
Tags
boston blog main
9
×
indiana blog main
9
×
indiana top stories
life sciences
national blog main
boston top stories
clinical trials
fda
national top stories
raleigh-durham blog main
raleigh-durham top stories
san francisco blog main
san francisco top stories
biotech
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
new york blog main
new york top stories
san diego blog main
san diego top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
national
eli lilly
cancer
amgen
drugs
migraine research foundation
teva pharmaceutical
blueprint medicines
calcitonin gene-related peptide
chronic migraine
deals
eptinezumab
What
drug
9
×
fda
9
×
approval
new
won
approved
cancer
migraine
therapy
bio
class
companies
decades
developed
drugs
friday
genetic
medicine
medicines
news
oks
oral
patients
roundup
second
time
acute
address
addresses
agency
aimmune
allergy
amgen
approves
aren’t
arguments
awarded
big
blueprint
candidates
Language
unset
Current search:
photo
×
fda
×
" boston blog main "
×
drug
×
" indiana blog main "
×
@xconomy.com
3 years ago
FDA Approves Blueprint Cancer Drug Targeting RET Genetic Signatures
@xconomy.com
4 years ago
Eisai Pulls Weight Loss Drug From Market After FDA Flags Cancer Risks
@xconomy.com
4 years ago
Aimmune Awarded First FDA Approval for a Peanut Allergy Therapy
@xconomy.com
4 years ago
FDA OKs Lilly’s Lasmiditan, First New Acute Migraine Drug in Decades
@xconomy.com
5 years ago
At Big Neuro Meeting, Migraine Drug Competitors to Make Oral Arguments
@xconomy.com
5 years ago
Bio Roundup: NASH News, Merck Strikes, Digital Tokens & More
@xconomy.com
5 years ago
Genetic Medicine: FDA OKs 2nd Cancer Drug that Targets DNA, not Tissues
@xconomy.com
5 years ago
Bio Roundup: Medicare Drug Prices, FDA Moves, Gene Therapy News & More
@xconomy.com
6 years ago
Amgen Migraine Drug Gets FDA Nod, First in New Class of Medicines